Association of Duration of Valproic Acid Treatment and Glycemic Indexes among Adult

Main Article Content

Santoso Jaeri
Kurnia Kusumastuti

Abstract

Introduction: Valproic acid (VA) is one of the commonly used for epilepsy, psychiatric problems, and recurrent mi- graine medication. Long-term use of VA maybe affects the metabolic processes, resulting in the gain of weight and disturbance of glycemic indexes which play an important role in cardiovascular consequences. Unfortunately, these impacts have not been fully understood. The study investigates the long-term impact of VA on the level of fasting blood sugar, 2-hour after-meal blood sugar and HbA1C among adults. Methods: An observational study with the cross-sectional study approach among forty participants (n=21, with less than 1-year medication, and n=19, with the 1 year or more medication) who fulfill the inclusion and exclusion criteria. The level of fasting blood sugar, 2 hours after-meal blood sugar, and HbA1C levels were examined. The two-independent T-test was performed to determine the statistical differences of the level of the fasting blood sugar, 2-hour after-meal blood sugar, and HbA1C from both groups. Results: There are no significant differences in most of the demographic and clinical characteristics of participants except for age, and there are no significant differences in the level of fasting blood sugar, 2-hour after-meal blood sugar, and HbA1C among both groups. Conclusion: There is no significant impact of long-term VA treatment on the homeostatis of blood sugar among adults measured by the level of fasting blood sugar, 2-hour after-meal blood sugar, and HbA1C.

Downloads

Download data is not yet available.

Article Details

How to Cite
Jaeri, S., & Kusumastuti, K. (2021). Association of Duration of Valproic Acid Treatment and Glycemic Indexes among Adult. Malaysian Journal of Medicine and Health Sciences, 17(4), 8–12. Retrieved from http://mjmhsojs.upm.edu.my/index.php/mjmhs/article/view/453
Section
Original Articles

References

Tomson T, Battino D, Perucca E. Valproic Acid After Five Decades of Use in epilepsy: Time to Reconsider the Indication of Time-honoured Drug. Lancet Neurol. 2015; 15: 1-9.

Fan H-C, Lee H-S, Chang K-P. The Impact of Anti- Epileptic Drugs on Growth and Bone Metabolism. Internat Journal of Molecular Sciences. 2016; 17: 1-22.

Ghodke-Puranik Y, Thorn CF, Lamba JK. Valproic Acid Pathway: Pharmacokinetics and Pharmacodynamics. Pharmacogenet Genomics. 2013; 23: 236-41.

Terbach N, Williams RSB. Structure-function Studies for The Panace, Valproic Acid. Biochemical Society Transaction. 2009; 37: 1126-32.

Tseng J-H, Chen C-Y, Chen P-C, Hsiao S-H, Fan C-C, Liang Y-C, Chen C-P. Valproic Acid Inhibits Glioblastoma Multiforme Cell Growth Via Paraoxonase 2 Expression. Oncotarget. 2017; 8(9): 14666-14679.

Coppola G, Piccorossi A, Operto FF, Verroti A. Anticonvulsant Drugs for generalized Tonic-Clonic Epilepsy. Expert Opinion on Pharmacotherapy. 2017.

Li H, Wang X, Zhou Y. Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. Internat Journal of Neuropsychopharmacology. 2015: 1-7.

Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic, and Endocrine Effects of valproic Acid Chronic Treatment. Epilepsy Research. 2013; 8:1-23.

Abaci A, Saygi M, Yis U, Demir K, Dirik E, Bober E. Metabolic Alterations During valproic Acid Treatment: A Prospective Study. Pediatr Neurol. 2009; 41: 435-9.

Chen S, Wu H, Klebe D, Hong Y, Zhang J. Valproic Acid: A New Candidate of Therapeutic Application for the Acute Central Nervous System Injuries. Neurochem Res. 2014.

Sakakura K, Nakano M, Otsuka F. Pathophysiology of Atherosclerosis Plaque Progression. Heart, Lung, and Circulation. 2013; 22: 399-411.

Plonka-Poltorak E, Zagrodzki P, Kryczyk-Koziol J. Does Valproate Therapy in Epileptic Patients Contribute to Changing Atherosclerosis Risk Factors? The Role of Lipids and Free Fatty Acids. Pharmacological Reports. 2016; 68: 1339-44.

Luo X, Zhang M, Deng L, Zhao J. Effects of Valproate on The Carotid Artery Intima-Media Thickness in Epileptics. Indian Journal of Pharmacology. 2015; 47: 45-8.

Erdemir A, Cullu N, Yis U. Evaluation of Serum Lipids and Carotid Artery Intima Media Thickness in Epileptic Children Treated with Valproic Acid. Brain & Development. 2009; 31: 713-6.

Auley MTM, Mooney KM. Computationally Modelling Lipid Metabolism and Aging: A Mini-review. Computational and Structural Biotechnology Journal. 2015; 13: 38-46.

Rakitin A. Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus? Front Endocrinol (Lausanne). 2017; 8(147):1-3.

Kusumastuti K, Jaeri S. The Effect of Long-term Valproic Acid Treatment in the Level of Total Cholesterol among Adult. Indian J Pharmacol. 2020;52(2):134-137.

Yedulla NR, Naik AR, Kokotovich KM, Yu W, Greenberg ML, Jena BP. Valproate Inhibits Glucose-Stimulated Insulin Secretion in Beta Cells. Histochemistry and Cell Biology. 2018; 150: 395-401.

Nisha Y, Bobby Z, Wadwekar V. Biochemical Derangements related to Metabolic Syndrome in Epileptic Patients on Treatment with valproic Acid. Seizure: European Journal of Epilepsy. 2018; 60: 57-60.

Khan S, Jena G. Valproic Acid Improves Glucose Homeostasis by Increasing Beta-Cell Proliferation, Function, and Reducing its Apoptosis through HDAC Inhibition in Juvenile Diabetic Rat. J Biochem Molecular Toxicology. 2016; 30: 438-46.

Rakitin A, Koks S, Haldre S. Valproate Modulates Glucose Metabolism in Patients with Epilepsy After First Exposure. Epilepsia. 2015; 56: e172-e5.

Quan W, Shao Q, Zhang H, Liu FH, Zhang XH. Acute Pancreatitis Associated with Valproate Treatment. Chin Med J (Engl). 2018; 131: 1889-90.